Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Director | December 18, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date December 18, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,762 |
Ending reported balance
After 2025-12-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-18 · Sale · Disposed 4,660 · Balance 9,223 F1: The shares were sold in multiple transactions at prices ranging from $67.00 to $67.28, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2025-12-18 · Sale · Disposed 461 · Balance 8,762 F2: The shares were sold in multiple transactions at prices ranging from $68.00 to $68.35, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in multiple transactions at prices ranging from $67.00 to $67.28, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F2: The shares were sold in multiple transactions at prices ranging from $68.00 to $68.35, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 19, 2025 20:43 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 461 | $68.09 | $31,389.49 |
DisclosureSEC source: 0001437749-25-038426 · rdgdoc.xml · nonDerivative · entry 2 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,762 F2 · price: The shares were sold in multiple transactions at prices ranging from $68.00 to $68.35, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 20:43 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 4,660 | $67.06 | $312,499.60 |
DisclosureSEC source: 0001437749-25-038426 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,223 F1 · price: The shares were sold in multiple transactions at prices ranging from $67.00 to $67.28, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 16, 2025 Filed Dec 17, 2025 20:41 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 7,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-038138 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,883 F1 · kind: Pro rata distribution from Gem Pharmaceuticals, LLC, of which the reporting person is a non-managing member. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 2,924 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037169 · rdgdoc.xml · derivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,924 Underlying: Common Stock · 2,924 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 00:58 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 11,365 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001437749-25-006726 · rdgdoc.xml · derivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,365 Underlying: Common Stock · 11,365 shares Expires 2035-03-04 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000484 · rdgdoc.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000484 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-027585 · rdgdoc.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,533 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-027585 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019260 · rdgdoc.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,066 Underlying: Common Stock · 2,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019260 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:20 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009336 · rdgdoc.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 2,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 10,133 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:20 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009336 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 10,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002517 · rdgdoc.xml · derivative · entry 2 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,133 Underlying: Common Stock · 10,133 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 13,930 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001437749-23-002517 · rdgdoc.xml · derivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,930 Underlying: Common Stock · 13,930 shares Expires 2033-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:09 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000171 · rdgdoc.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:09 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000171 · rdgdoc.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013279 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-013279 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:19 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009151 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,718 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:19 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-009151 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-004481 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-004481 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:30 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 11,436 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001168 · section16.xml · derivative · entry 2 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436 Underlying: Common Stock · 11,436 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:30 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 15,128 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001168 · section16.xml · derivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,128 Underlying: Common Stock · 15,128 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000114 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000114 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:26 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010716 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:26 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-010716 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 752 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007599 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502 Underlying: Common Stock · 752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-007599 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-003793 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,254 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-003793 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000923 · section16.xml · derivative · entry 2 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 4,443 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001654954-21-000923 · section16.xml · derivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Underlying: Common Stock · 4,443 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000150 · section16.xml · derivative · entry 5 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000150 · section16.xml · nonDerivative · entry 2 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 22:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000150 · section16.xml · derivative · entry 4 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 22:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000150 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-007301 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644 Underlying: Common Stock · 323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-007301 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 18:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-003676 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 18:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-003676 · section16.xml · nonDerivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 01:54 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 5,646 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001654954-20-001791 · section16.xml · derivative · entry 2 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,646 Underlying: Common Stock · 5,646 shares Expires 2030-01-31 F2 · derivative.exercise_date: Stock options vest 25% on March 31, 2020, 25% on June 30, 2020, 25% on September 30, 2020, and 25% on December 31, 2020. Read SEC document |
| January 31, 2020 Filed Feb 21, 2020 01:54 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 1,289 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-20-001791 · section16.xml · derivative · entry 1 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289 Underlying: Common Stock · 1,289 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock units vest 25% on April 1, 2020, 25% on July 1, 2020, 25% on October 1, 2020, and 25% on January 1, 2021. F1 · derivative.expiration_date: Restricted stock units vest 25% on April 1, 2020, 25% on July 1, 2020, 25% on October 1, 2020, and 25% on January 1, 2021. Read SEC document |
| August 09, 2018 Filed Sep 27, 2018 22:42 UTC | Monopar Therapeutics NONE · Entity 5152 | GrantStock options · Derivative | 26,100 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-18-010576 · section16.xml · derivative · entry 3 KLAUSNER ARTHUR J · CIK 0001207790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,100 Underlying: Common stock · 26,100 shares Expires 2028-08-08 F2 · derivative.exercise_date: Stock options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.